Iron-induced epigenetic abnormalities of mouse bone marrow through aberrant activation of aconitase and isocitrate dehydrogenase

In vivo behavior of NTBI revealed by automated quantification system

(2016) Satoshi Ito et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Aging, clonal hematopoiesis and preleukemia: not just bad luck?

(2015) Liran I. Shlush et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

CpG island methylator phenotype of myelodysplastic syndrome identified through genome-wide profiling of DNA methylation and gene expression

(2014) Xiaoli Zhao et al.   BRITISH JOURNAL OF HAEMATOLOGY

High levels of global DNA methylation are an independent adverse prognostic factor in a series of 90 patients with de novo myelodysplastic syndrome

(2014) Xavier Calvo et al.   LEUKEMIA RESEARCH

Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis

(2014) Jie Jin et al.   PLoS One

What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer

(2013) J.-A. Losman et al.   GENES & DEVELOPMENT

Serum 2-Hydroxyglutarate Production in IDH1- and IDH2-Mutated De Novo Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group

(2013) Maxime Janin et al.   JOURNAL OF CLINICAL ONCOLOGY

The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases

(2013) E Solary et al.   LEUKEMIA

Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry

(2013) Roger M. Lyons et al.   LEUKEMIA RESEARCH

Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities

(2013) R. A. Cairns et al.   Cancer Discovery

Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG

(2013) Anna C Navis et al.   Acta Neuropathologica Communications

The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System Neoplasms

(2013) Dinesh Rakheja et al.   Frontiers in Oncology

Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response

(2012) A. T. Fathi et al.   BLOOD

Myeloid malignancies: mutations, models and management

(2012) Anne Murati et al.   BMC CANCER

Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes

(2012) N. Gattermann et al.   HAEMATOLOGICA

Epigenetic aspects of MDS and its molecular targeted therapy

(2012) Jumpei Yamazaki et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients

(2012) Sadudee Chotirat et al.   Journal of Hematology & Oncology

Improved survival in MDS patients receiving iron chelation therapy – A matched pair analysis of 188 patients from the Düsseldorf MDS registry

(2012) Judith Neukirchen et al.   LEUKEMIA RESEARCH

Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation

(2012) J. Lazovic et al.   NEURO-ONCOLOGY

Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy

(2011) Whitney B. Pope et al.   JOURNAL OF NEURO-ONCOLOGY

IDH1 and IDH2 mutations in pediatric acute leukemia

(2011) A K Andersson et al.   LEUKEMIA

Deferasirox Treatment Interruption in a Transfusion-Requiring Myelodysplastic Patient Led to Loss of Erythroid Response

(2010) Massimo Breccia et al.   ACTA HAEMATOLOGICA

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

(2010) Patrick S. Ward et al.   CANCER CELL

Epigenetic Changes in the Myelodysplastic Syndrome

(2010) Jean-Pierre Issa   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

(2010) Stefan Gross et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM

(2010) Christian Rose et al.   LEUKEMIA RESEARCH

Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: A brief review

(2010) Roberto Guariglia et al.   LEUKEMIA RESEARCH

Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients

(2010) Esther Natalie Oliva et al.   TRANSFUSION

DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes

(2009) Lanlan Shen et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE